The efficacy and safety of tislelizumab plus anlotinib as first-line treatment in advanced pulmonary sarcomatoid carcinoma: a single-arm phase II trial
The combination of tislelizumab and anlotinib demonstrated promising antitumor activity with a manageable safety profile as first-line therapy in patients with advanced PSC.
Authors
- Fujuan Zeng
- Li Huang (ORCID: https://orcid.org/0000-0003-3910-3982)
- Anwen Liu (ORCID: https://orcid.org/0009-0004-9534-2317)
- Wenqian Huang
- Xiaoqiang Zhang
- Le Xiong
- Jing Cai
- Zhimin Zeng
- Ziye Chen
- Chenyi Liu
- Yue’e Zheng
Institutions
- Nanchang University (CN)
- Jiangxi University of Technology (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Jiangxi Agricultural University (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4770
- Primary Topic
- Metastasis and carcinoma case studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00